Why the Polynovo share price could climb in August

The Polynovo Ltd (ASX: PNV) has had a strong year but I think it could push even higher after its August earnings result.

| More on:
Rocket launching into space

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Polynovo Ltd (ASX: PNV) share price could be set to push higher in 2020.

Here's why I see some tailwinds behind the Aussie biotech ahead of its August earnings result.

How has the Polynovo share price performed recently?

The Polynovo share price jumped 0.45% higher yesterday and is now up 21.0% in 2020. That's a strong result given the S&P/ASX 200 Index (ASX: XJO) is down 8.9% over the same period.

However, that performance pales in comparison to Polynovo's 5-year track record. Shares in the Aussie biotech are up 1,945.5% in the last 5 years despite being down 31.4% from their all-time high.

It's been a bullish run in recent years but investors want to know what sort of growth they can expect in the future.

What's been driving these share price moves?

July has been a busy month for Polynovo announcements despite the company's share price falling 14.1% lower.

Polynovo received formal feedback from the United States Food and Drug Administration (FDA) on its Pivotal trial protocol. The Pivotal trial program is assessing the use of NovoSorb BTM in the treatment of full thickness burns.

The FDA has requested further information from the company which Polynovo Managing Director, Paul Brennan, described as 'positive'.

Polynovo also received US$15 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to support the Pivotal trial program.

The company provided a trading update on 10 July which contained some more positive signs for shareholders. This was highlighted by June 2020 being a new record US sales month for the Aussie biotech company.

Sales for the June quarter climbed 33% compared to the March quarter with FY20 product sales 'likely to at least double FY19'. It's yet another strong milestone that has supported the recent Polynovo share price growth.

There was also a solid breakthrough in the United Kingdom as the company announced its first sale. Positively, there have also been 'numerous applications' of the NovoSorb BTM product across Germany, Austria and Switzerland.

What am I expecting from the August result?

I'm quietly confident about Polynovo's August full-year results.

The strong sales trajectory has been maintained by the company for quite some time now.

Polynovo continues to explore new and innovative applications of NovoSorb BTM. That says to me that there is plenty of potential growth left in the Polynovo share price in 2020.

All in all, I think we'll see some strong earnings numbers next month. That could propel the company's value even higher and fuel further outperformance.

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »